Anavex Expanding Boundaries
        in Drug Discovery
HOME  |  ABOUT US  |  PIPELINE  |  R & D  |  PUBLICATIONS  |  PARTNERING  |  INVESTORS  |  CAREERS  |  CONTACT
LATEST NEWS
07/21/2014
Anavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies
07/14/2014
ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer's Hallmarks in Preclinical Disease Model
06/30/2014
Anavex Announces Report Expanding Opportunity for Therapeutic Application of Anavex Compounds
more
Anavex Corporate Presentation
Spring 2014
Watch webcast from Anavex Corporate
Presentation at Noble Equity Conference
on January 21, 2014.
MEDIA COVERAGE
Success Stories: Trending toward multiple pathways
The Anticipated Clinical Effect of the new
Alzheimer Drug ANAVEX PLUS in a Predictive
Humanised Cortical Cognitive Model for
Alzheimer's Disease
EMAIL UPDATES

 

Anavex Life Sciences Corp. has a productive drug discovery platform with a broad IP portfolio based on unique expertise of sigma receptors ligands. ANAVEX 2-73 has succesfully completed a Phase 1 single ascending dose clinical trial of ANAVEX 2-73, lead drug candidate for the treatment of Alzheimer’s Disease (AD). Several other new drug candidates with high affinity for sigma receptors are close to entering Phase 1 clinical trials. The synergetic effects of sigma receptors offer a new neuroprotective mechanism in AD and other Central Nervous System disorders such as epilepsy and depression. Anavex proprietary sigma ligands induce apoptosis in cancer cells in a selective way. Anavex oncology candidates show promising pro-apoptotic activity in several in vivo models of solid tumors.

According to 2011 Alzheimer’s Disease Facts and Figures, released by the Alzheimer’s Association, there are nearly 15 million Alzheimer’s and dementia caregivers in the United States. This new report shows that there are far more Alzheimer’s and dementia caregivers than previously believed 37% more than reported last year. These individuals provided 17 billion hours of unpaid care valued at $202.6 billion. If Alzheimer’s and dementia caregivers were the only residents of a single state it would be the 5th largest state in the country. more

ARTICLES ON ALZHEIMER’S
A rich portfolio of drug candidates with new mechanism of action, targeting Alzheimer’s Disease and Cancer.
© 2007-2014 Anavex Life Sciences Corp. - All Rights Reserved.